Likewise, a study included 3,177 patients with HER2 + breast cancer [39] showed a significantly favorable survival in patients with HR + /HER2 + subgroup compared with HR-/HER2 + subtype with the receipt of standard adjuvant therapeutics. This evidence concerns the gene ERBB2 and breast carcinoma.